JP2007505888A - オキシトシン拮抗薬としての置換トリアゾール誘導体 - Google Patents

オキシトシン拮抗薬としての置換トリアゾール誘導体 Download PDF

Info

Publication number
JP2007505888A
JP2007505888A JP2006526721A JP2006526721A JP2007505888A JP 2007505888 A JP2007505888 A JP 2007505888A JP 2006526721 A JP2006526721 A JP 2006526721A JP 2006526721 A JP2006526721 A JP 2006526721A JP 2007505888 A JP2007505888 A JP 2007505888A
Authority
JP
Japan
Prior art keywords
methoxypyridin
triazol
methyl
fluoro
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505888A5 (nl
Inventor
アラン・ダニエル・ブラウン
デイヴィッド・エリス
クリストファー・ロナルド・スミス
Original Assignee
ファイザー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by ファイザー インコーポレイテッド filed Critical ファイザー インコーポレイテッド
Publication of JP2007505888A publication Critical patent/JP2007505888A/ja
Publication of JP2007505888A5 publication Critical patent/JP2007505888A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006526721A 2003-09-22 2004-09-10 オキシトシン拮抗薬としての置換トリアゾール誘導体 Pending JP2007505888A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists
PCT/IB2004/002977 WO2005028452A1 (en) 2003-09-22 2004-09-10 Substituted triazole derivatives as oxytocin antagonists

Publications (2)

Publication Number Publication Date
JP2007505888A true JP2007505888A (ja) 2007-03-15
JP2007505888A5 JP2007505888A5 (nl) 2007-10-25

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526721A Pending JP2007505888A (ja) 2003-09-22 2004-09-10 オキシトシン拮抗薬としての置換トリアゾール誘導体

Country Status (12)

Country Link
EP (1) EP1673355A1 (nl)
JP (1) JP2007505888A (nl)
AR (1) AR045791A1 (nl)
BR (1) BRPI0414663A (nl)
CA (1) CA2539297C (nl)
MX (1) MXPA06003158A (nl)
NL (1) NL1027084C2 (nl)
PA (1) PA8613001A1 (nl)
PE (1) PE20050950A1 (nl)
TW (1) TW200526606A (nl)
UY (1) UY28524A1 (nl)
WO (1) WO2005028452A1 (nl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
CN103554042B (zh) * 2004-11-18 2016-08-10 Synta医药公司 调节hsp90活性的三唑化合物
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
AP3272A (en) 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
RU2019118993A (ru) * 2016-12-21 2021-01-22 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное азациклобутилтриазола с конденсированной кольцевой группой, способ его получения и его применение в медицине
CN113149961B (zh) 2016-12-28 2022-11-22 江苏恒瑞医药股份有限公司 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用
WO2019242642A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (fr) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
WO2001087855A1 (fr) * 2000-05-19 2001-11-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
WO2003053437A1 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1273580B1 (en) * 2001-07-05 2005-06-15 Pfizer Products Inc. Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (fr) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
WO2001087855A1 (fr) * 2000-05-19 2001-11-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
WO2003053437A1 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles as oxytocin antagonists

Also Published As

Publication number Publication date
CA2539297C (en) 2010-07-20
AR045791A1 (es) 2005-11-16
NL1027084A1 (nl) 2005-03-24
CA2539297A1 (en) 2005-03-31
WO2005028452A9 (en) 2005-07-21
MXPA06003158A (es) 2006-06-05
UY28524A1 (es) 2005-04-29
PE20050950A1 (es) 2005-11-11
WO2005028452A1 (en) 2005-03-31
TW200526606A (en) 2005-08-16
EP1673355A1 (en) 2006-06-28
NL1027084C2 (nl) 2006-01-24
PA8613001A1 (es) 2005-08-04
BRPI0414663A (pt) 2006-11-21

Similar Documents

Publication Publication Date Title
JP4124805B1 (ja) オキシトシンアンタゴニストとしての置換トリアゾール誘導体
US20070185078A1 (en) Substituted triazole derivatives as oxytocin antagonists
US20080214622A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
WO2005082866A2 (en) Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
JP2007534740A (ja) バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
JP2008531679A (ja) オキシトシンアンタゴニストとしての１，２，４−トリアゾール誘導体とその使用
JP2007505888A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
US7875615B2 (en) Substituted triazole derivatives as oxytocin antagonists
CA2602198C (en) Substituted triazole derivatives as oxytocin antagonists
JP2009504628A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070906

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090210

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110627